Inflamed moods: A review of the interactions between inflammation and mood disorders

@article{Rosenblat2014InflamedMA,
  title={Inflamed moods: A review of the interactions between inflammation and mood disorders},
  author={Joshua D. Rosenblat and Danielle S Cha and Rodrigo B. Mansur and Roger S. McIntyre},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2014},
  volume={53},
  pages={23-34}
}
Mood disorders have been recognized by the World Health Organization (WHO) as the leading cause of disability worldwide. Notwithstanding the established efficacy of conventional mood agents, many treated individuals continue to remain treatment refractory and/or exhibit clinically significant residual symptoms, cognitive dysfunction, and psychosocial impairment. Therefore, a priority research and clinical agenda is to identify pathophysiological mechanisms subserving mood disorders to improve… Expand
Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders
TLDR
Evidence implicating inflammation in various effector systems in mood disorders is highlighted, with a particular focus on the intercommunication with glutamatergic signaling, immune system signaling, as well as metabolic parameters (eg, L-methyl folate bioavailability). Expand
Role of neuro-immunological factors in the pathophysiology of mood disorders
TLDR
Evidence that the release of neuroactive cytokines, particularly interleukins such as IL-1β, IL-6, and TNF-α, is altered in these disorders is reviewed and mechanisms such as the ATP-gated ion channel P2X7, through which cytokine signaling can influence neuro-glial interactions are discussed. Expand
Bipolar Disorder and Immune Dysfunction: Epidemiological Findings, Proposed Pathophysiology and Clinical Implications
TLDR
The inflammatory-mood pathway presents several potential novel targets in the treatment of BD, and proof-of-concept clinical trials have shown a positive effect of anti-inflammatory agents in thetreatment of BD; however, further research is needed to determine the clinical utility of these treatments. Expand
Role of Neuro-Immunological Factors in the Pathophysiology of Mood Disorders: Implications for Novel Therapeutics for Treatment Resistant Depression.
TLDR
Evidence that the compounds that reduce the release or signaling of neuroactive cytokines, particularly IL-1β, IL-6, and TNF-α, can exert antidepressant effects in subgroups of depressed patients who are identified by blood-based biomarkers associated with inflammation is reviewed. Expand
IMMUNE SYSTEM ALTERATIONS AND EXCITATORY SYMPTOMS IN AFFECTIVE DISORDERS
Neuroinflammation has been proposed as a strong biological factor underlying the development of neuropsychiatric diseases. A role for dysregulation of the immune system was initially suggested inExpand
Inflammatory Mediators in Mood Disorders: Therapeutic Opportunities.
TLDR
The field of psychoneuroimmunology is one of great therapeutic opportunity, yielding experimental therapeutics for mood disorders, such as peripheral cytokine targeting antibodies, microglia and astrocyte targeting therapies, and probiotic treatments for gut dysbiosis, and producing findings that identify therapeutic targets for future development. Expand
Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: Evidence, pathophysiology and treatment implications.
TLDR
Several studies suggest that immune dysfunction is associated with cognitive impairment in BD, and future investigations of anti-inflammatory agents targeting cognitive function as a treatment outcome are merited. Expand
Therapeutic Strategies for Treatment of Inflammation-related Depression
TLDR
Anti-inflammatory add-on therapy in depression highlights such treatment as a candidate for enhancement strategy in patients with moderate-to-severe depression, and the interactions between the immune system and CNS are not only involved in shaping behavior, but also in responding to therapeutics. Expand
Inflammation in Bipolar Disorder (BD): Identification of New Therapeutic Targets.
TLDR
Recent data regarding inflammation in bipolar disorder is discussed, unveiling potential therapeutic approaches through direct or indirect modulation of inflammatory response. Expand
Exploring the Physiological Link between Psoriasis and Mood Disorders
TLDR
Recognition of psychiatric comorbidity is an imperative first step in effectively treating these patients as a whole, and evidence that improvement in mood decreases psoriasis severity underscores how psychological awareness can be critical to clinicians in their practice. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 237 REFERENCES
Mood Disorders and Obesity: Understanding Inflammation as a Pathophysiological Nexus
TLDR
It is indicated that obesity and mood disorders are chronic low-grade pro-inflammatory states that result in a gradual accumulation of allostatic load and practitioners should screen individuals with obesity for the presence of clinically significant depressive symptoms. Expand
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
TLDR
It is suggested that elevated immune-inflammatory signaling is a mechanism that is relevant to the pathoetiology of mood disorders, and may therefore represent a new therapeutic target for the development of more effective treatments. Expand
Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness
TLDR
Aspirin, one of the oldest agents in medicine, is a potential new therapy for a range of neuropsychiatric disorders, and may provide proof-of-principle support for the role of inflammation and O&NS in the pathophysiology of this diverse group of disorders. Expand
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
TLDR
Preliminary data from patients with inflammatory disorders, as well as medically healthy depressed patients, suggest that inhibiting proinflammatory cytokines or their signaling pathways may improve depressed mood and increase treatment response to conventional antidepressant medication. Expand
Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications
TLDR
This review explores the idea that specific gene polymorphisms and neurotransmitter systems can confer protection from or vulnerability to specific symptom dimensions of cytokine-related depression and potential therapeutic strategies that target inflammatory cytokine signaling. Expand
Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management
TLDR
Evidence‐based pharmacological and psychological treatments for anxiety and depression are reviewed and practical considerations in treating these conditions in the context of IBD to facilitate overall management of the IBD patient are discussed. Expand
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature.
TLDR
Inflammation appears relevant to bipolar disorder across several important domains and further research is warranted to parse the reciprocal associations between inflammation and symptoms, comorbidities, and treatments in bipolar disorder. Expand
Neuroimmunological effects of physical exercise in depression
TLDR
In pre-clinical models exercise attenuates stress-related depression-like behaviours and may reduce inflammation and oxidation stress via a multitude of cellular and humoral neuroimmune changes. Expand
Are mood disorders and obesity related? A review for the mental health professional.
TLDR
Although the overlap between mood disorders and obesity may be coincidental, it suggests the two conditions may be related. Expand
Cytokine profiles in bipolar affective disorder: focus on acutely ill patients.
TLDR
BPAD is associated with increased production of pro-inflammatory cytokines both in the manic and in the depressed phase as compared to healthy subjects. Expand
...
1
2
3
4
5
...